SPIKEVAX (Moderna Australia Pty Ltd)
Product name
SPIKEVAX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
132 (255 working days)
Active ingredients
SARS-CoV-2 spike protein (mRNA) LP.8.1
Registration type
NCE/NBE
Indication
SPIKEVAX LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 Vaccine is indicated for:
Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older.
The use of this vaccine should be in accordance with official recommendations.